Not surprisingly, my reason for posting is primarily the Levothyroxine section (around a third of the way through).
That section references (Saravanan et al. 2007) and (Jonklaas et al. 2008) - and simply accepts their conclusions that liothyronine and combination products have little or no justification as all of us can be well with levothyroxine monotherapy.
I don't think anyone disputes that any dosing with liothyronine causes relative T3 peaks in the blood. But that simple fact appears to be taken as proof that including liothyronine in any form or regime is necessarily inferior to levothyroxine monotherapy.
The 10 top prescribed medicines in Germany from 1985 to 2022: pharmacological analysis
Research
Open access
Published: 21 November 2024
Open access here: